Properties of the measures to assess oxaliplatin-induced peripheral neuropathy: A literature review

Sang Hui Chu, Yoon Ju Lee, Young Joo Lee, Charles S. Cleeland

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Purpose: The purpose of this study is to provide a comprehensive overview of the various measures available for assessment of oxaliplatin-induced peripheral neuropathy (OXLIPN) and to evaluate the measurement properties of each assessment tool. Methods: A systematic review was conducted to identify existing measures for OXLIPN found in the databases of PubMed, Cochrane Library, Embase, RISS and KoreaMed. The quality of the 24 identified tools was evaluated based on their properties of measurement including content validity, internal consistency, criterion validity, construct validity, reproducibility, responsiveness, floor-ceiling effects and interpretability. Results: Ten (41.7%) of the 24 tools were identified as specific measures for assessing OXLIPN and the most popular type of measures were clinical grading systems by clinicians (58.3%) and only 29.2% of measures were identified as patient reported outcomes. The most frequently used tool was National Cancer Institute–Common Toxicity Criteria (NCI-CTC), but the validity of NCI-CTC has not been reported appropriately. Overall, the Neuropathic Pain Symptom Inventory (NPSI) received the best psychometric scores, and the Chemotherapy-induced Peripheral Neuropathy Assessment Tool (CIPNAT) and Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group–neurotoxicity-12 (FACT/GOG-Ntx-12) followed NPSI. Conclusion: To select appropriate measure, evidences should be accumulated through the clinical use of tools. Therefore, practitioner and researchers are urged to report relevant statistics required for the validation of the currently used measures for assessment of OXLIPN.

Original languageEnglish
Pages (from-to)783-801
Number of pages19
JournalJournal of Korean Academy of Nursing
Volume45
Issue number6
DOIs
Publication statusPublished - 2015 Dec 1

Fingerprint

oxaliplatin
Peripheral Nervous System Diseases
Neuralgia
Equipment and Supplies
Neoplasms
Psychometrics
PubMed
Libraries
Research Personnel
Databases
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Nursing(all)

Cite this

Chu, Sang Hui ; Lee, Yoon Ju ; Lee, Young Joo ; Cleeland, Charles S. / Properties of the measures to assess oxaliplatin-induced peripheral neuropathy : A literature review. In: Journal of Korean Academy of Nursing. 2015 ; Vol. 45, No. 6. pp. 783-801.
@article{06bbd037c11a4e00b992529d48e562e1,
title = "Properties of the measures to assess oxaliplatin-induced peripheral neuropathy: A literature review",
abstract = "Purpose: The purpose of this study is to provide a comprehensive overview of the various measures available for assessment of oxaliplatin-induced peripheral neuropathy (OXLIPN) and to evaluate the measurement properties of each assessment tool. Methods: A systematic review was conducted to identify existing measures for OXLIPN found in the databases of PubMed, Cochrane Library, Embase, RISS and KoreaMed. The quality of the 24 identified tools was evaluated based on their properties of measurement including content validity, internal consistency, criterion validity, construct validity, reproducibility, responsiveness, floor-ceiling effects and interpretability. Results: Ten (41.7{\%}) of the 24 tools were identified as specific measures for assessing OXLIPN and the most popular type of measures were clinical grading systems by clinicians (58.3{\%}) and only 29.2{\%} of measures were identified as patient reported outcomes. The most frequently used tool was National Cancer Institute–Common Toxicity Criteria (NCI-CTC), but the validity of NCI-CTC has not been reported appropriately. Overall, the Neuropathic Pain Symptom Inventory (NPSI) received the best psychometric scores, and the Chemotherapy-induced Peripheral Neuropathy Assessment Tool (CIPNAT) and Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group–neurotoxicity-12 (FACT/GOG-Ntx-12) followed NPSI. Conclusion: To select appropriate measure, evidences should be accumulated through the clinical use of tools. Therefore, practitioner and researchers are urged to report relevant statistics required for the validation of the currently used measures for assessment of OXLIPN.",
author = "Chu, {Sang Hui} and Lee, {Yoon Ju} and Lee, {Young Joo} and Cleeland, {Charles S.}",
year = "2015",
month = "12",
day = "1",
doi = "10.4040/jkan.2015.45.6.783",
language = "English",
volume = "45",
pages = "783--801",
journal = "Journal of Korean Academy of Nursing",
issn = "2005-3673",
publisher = "Korean Society of Nursing Science",
number = "6",

}

Properties of the measures to assess oxaliplatin-induced peripheral neuropathy : A literature review. / Chu, Sang Hui; Lee, Yoon Ju; Lee, Young Joo; Cleeland, Charles S.

In: Journal of Korean Academy of Nursing, Vol. 45, No. 6, 01.12.2015, p. 783-801.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Properties of the measures to assess oxaliplatin-induced peripheral neuropathy

T2 - A literature review

AU - Chu, Sang Hui

AU - Lee, Yoon Ju

AU - Lee, Young Joo

AU - Cleeland, Charles S.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Purpose: The purpose of this study is to provide a comprehensive overview of the various measures available for assessment of oxaliplatin-induced peripheral neuropathy (OXLIPN) and to evaluate the measurement properties of each assessment tool. Methods: A systematic review was conducted to identify existing measures for OXLIPN found in the databases of PubMed, Cochrane Library, Embase, RISS and KoreaMed. The quality of the 24 identified tools was evaluated based on their properties of measurement including content validity, internal consistency, criterion validity, construct validity, reproducibility, responsiveness, floor-ceiling effects and interpretability. Results: Ten (41.7%) of the 24 tools were identified as specific measures for assessing OXLIPN and the most popular type of measures were clinical grading systems by clinicians (58.3%) and only 29.2% of measures were identified as patient reported outcomes. The most frequently used tool was National Cancer Institute–Common Toxicity Criteria (NCI-CTC), but the validity of NCI-CTC has not been reported appropriately. Overall, the Neuropathic Pain Symptom Inventory (NPSI) received the best psychometric scores, and the Chemotherapy-induced Peripheral Neuropathy Assessment Tool (CIPNAT) and Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group–neurotoxicity-12 (FACT/GOG-Ntx-12) followed NPSI. Conclusion: To select appropriate measure, evidences should be accumulated through the clinical use of tools. Therefore, practitioner and researchers are urged to report relevant statistics required for the validation of the currently used measures for assessment of OXLIPN.

AB - Purpose: The purpose of this study is to provide a comprehensive overview of the various measures available for assessment of oxaliplatin-induced peripheral neuropathy (OXLIPN) and to evaluate the measurement properties of each assessment tool. Methods: A systematic review was conducted to identify existing measures for OXLIPN found in the databases of PubMed, Cochrane Library, Embase, RISS and KoreaMed. The quality of the 24 identified tools was evaluated based on their properties of measurement including content validity, internal consistency, criterion validity, construct validity, reproducibility, responsiveness, floor-ceiling effects and interpretability. Results: Ten (41.7%) of the 24 tools were identified as specific measures for assessing OXLIPN and the most popular type of measures were clinical grading systems by clinicians (58.3%) and only 29.2% of measures were identified as patient reported outcomes. The most frequently used tool was National Cancer Institute–Common Toxicity Criteria (NCI-CTC), but the validity of NCI-CTC has not been reported appropriately. Overall, the Neuropathic Pain Symptom Inventory (NPSI) received the best psychometric scores, and the Chemotherapy-induced Peripheral Neuropathy Assessment Tool (CIPNAT) and Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group–neurotoxicity-12 (FACT/GOG-Ntx-12) followed NPSI. Conclusion: To select appropriate measure, evidences should be accumulated through the clinical use of tools. Therefore, practitioner and researchers are urged to report relevant statistics required for the validation of the currently used measures for assessment of OXLIPN.

UR - http://www.scopus.com/inward/record.url?scp=84955148997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955148997&partnerID=8YFLogxK

U2 - 10.4040/jkan.2015.45.6.783

DO - 10.4040/jkan.2015.45.6.783

M3 - Review article

C2 - 26805492

AN - SCOPUS:84955148997

VL - 45

SP - 783

EP - 801

JO - Journal of Korean Academy of Nursing

JF - Journal of Korean Academy of Nursing

SN - 2005-3673

IS - 6

ER -